190 related articles for article (PubMed ID: 10677119)
1. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.
Lee YC; Knox BS; Garrett JE
Aust N Z J Med; 1999 Dec; 29(6):765-9. PubMed ID: 10677119
[TBL] [Abstract][Full Text] [Related]
2. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of CYFRA 21-1 in malignant pleural effusion.
Dejsomritrutai W; Senawong S; Promkiamon B
Respirology; 2001 Sep; 6(3):213-6. PubMed ID: 11555379
[TBL] [Abstract][Full Text] [Related]
4. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions.
Romero S; Fernández C; Arriero JM; Espasa A; Candela A; Martín C; Sánchez-Payá J
Eur Respir J; 1996 Jan; 9(1):17-23. PubMed ID: 8834328
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.
Salama G; Miédougé M; Rouzaud P; Mauduyt MA; Pujazon MC; Vincent C; Carles P; Serre G
Br J Cancer; 1998; 77(3):472-6. PubMed ID: 9472646
[TBL] [Abstract][Full Text] [Related]
6. Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers.
Fazli Khalaf F; Asadi Gharabaghi M; Balibegloo M; Davari H; Afshar S; Jahanbin B
Int J Biol Markers; 2023 Jun; 38(2):81-88. PubMed ID: 36942429
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions.
Ferrer J; Villarino MA; Encabo G; Felip E; Bermejo B; Vilà S; Orriols R
Cancer; 1999 Oct; 86(8):1488-95. PubMed ID: 10526277
[TBL] [Abstract][Full Text] [Related]
11. Different expression of FoxM1 in human benign and malignant pleural effusion.
Tang Z; Li H; Zhu H; Bai C
Med Oncol; 2015 Jan; 32(1):312. PubMed ID: 25491139
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic usefulness of tumour marker levels in pleural effusions of malignant and benign origin.
Kuralay F; Tokgöz Z; Cömlekci A
Clin Chim Acta; 2000 Oct; 300(1-2):43-55. PubMed ID: 10958862
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
14. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Wei F; Wei Y; Li LF; Li GL; Wang GJ
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
[No Abstract] [Full Text] [Related]
15. Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array.
Braunschweig T; Chung JY; Choi CH; Cho H; Chen QR; Xie R; Perry C; Khan J; Hewitt SM
Diagn Pathol; 2015 May; 10():53. PubMed ID: 26022333
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions.
Korczynski P; Krenke R; Safianowska A; Gorska K; Abou Chaz MB; Maskey-Warzechowska M; Kondracka A; Nasilowski J; Chazan R
Eur J Med Res; 2009 Dec; 14 Suppl 4(Suppl 4):128-33. PubMed ID: 20156743
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions.
Alataş F; Alataş O; Metintaş M; Colak O; Harmanci E; Demir S
Lung Cancer; 2001 Jan; 31(1):9-16. PubMed ID: 11162861
[TBL] [Abstract][Full Text] [Related]
18. Superoxide dismutase 2 as a marker to differentiate tuberculous pleural effusions from malignant pleural effusions.
Wang M; Zhang Z; Wang X
Clinics (Sao Paulo); 2014; 69(12):799-803. PubMed ID: 25627990
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemistry and ELISA quantitation of mucin for diagnosis of malignant pleural effusions.
Yang PC; Luh KT; Kuo SH; Wu CW
Am Rev Respir Dis; 1992 Dec; 146(6):1571-5. PubMed ID: 1456577
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Accuracy of CYFRA21-1 in the Differential Diagnosis of Pleural Effusions.
Trapé J; Sant F; Montesinos J; Arnau A; Sala M; Bernadich O; Martín E; Perich D; Lopez J; Ros S; Esteve-Valverde E; Pérez R; González-Fernández C; Aligue J; Catot S; Domenech M; Ruiz D; Bonet M; Molina R; Ordeig J
Anticancer Res; 2019 Sep; 39(9):5071-5076. PubMed ID: 31519617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
